Shopping Cart
Remove All
Your shopping cart is currently empty
K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer. |
| In vitro | K882 (0.5-8 μM, 24-72 h) significantly inhibits the proliferation, migration, and invasion of NCI-H358 cells with the KRAS G12C mutation [1]. |
| In vivo | Administered via intraperitoneal injection at a dosage of 25-100 mg/kg once daily for 31 days, K882 inhibits the growth of KRAS G12C mutant NSCLC xenograft tumors in the NCI-H358 xenograft mouse model [1]. |
| Molecular Weight | 292.33 |
| Formula | C18H16N2O2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.